ArticlePLOS global public health2026
Overall survival and associated factors among patients with pulmonary Kaposi's sarcoma in sub-Saharan Africa.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral Kaposi's sarcoma (KS), like pulmonary KS (PKS), is more common in HIV associated/epidemic KS (EpKS). Its presentation often mimics other opportunistic pulmonary infections and is associated with poor outcomes. This study investigated the prevalence of PKS, and factors associated with overall survival at a tertiary hospital in Tanzania. This retrospective study reviewed records of 269 histologically confirmed cutaneous KS patients treated at the Ocean Road Cancer Institute between January 2019 and December 2022. Sociodemographic, clinical, and survival data were extracted from patients' files. Specialist radiologists reviewed chest radiographs taken at the time of diagnosis, categorizing them as normal, infectious infiltrates, or PKS. Data were analyzed using descriptive statistics, and Cox Proportional Hazard model identified factors linked to overall survival. Statistical significance was defined as p < 0.05. Among 269 patients with cutaneous KS, 195 had EpKS, 66 had Endemic KS (EnKS), and 8 had unknown HIV status and were excluded from further analysis. The male-to-female ratio was 2:1. While all patients had cutaneous KS lesions, 23 (8.8%) had PKS which was significantly more common in the EpKS than EnKS group (p = 0.024). Additionally, 24 patients (9.2%) had Chest X-ray findings (CXR) indicative of infection. At one year, overall survival was 53% for patients with PKS, compared with 87% for those without PKS. In the adjusted analysis, patients without PKS had an 86% lower risk of mortality than those with PKS (aHR = 0.14; 95% CI: 0.07-0.32; P < 0.001). There is high prevalence of advanced KS presentation and poor overall survival especially among PKS in SSA, despite widespread ART use. Although CXR remains the diagnostic mainstay in this setting, it is subject to notable limitations. Simple, low-cost diagnostic algorithms are needed to optimize CXR utility alongside the ongoing expansion of advanced imaging and bronchoscopic services in the region.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.